SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel

South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA) for its epilepsy medication Cenobamate (local name Ecopri) on April 30. 

The application was submitted by Dexcel Pharma, the Israeli partner of SK Biopharmaceuticals. The approved drug includes a total of six dosages: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamate, an independently developed epilepsy drug by SK Biopharmaceuticals, was recognized for its efficacy in treating partial-onset seizures in adults and received marketing approval from the US Food and Drug Administration (FDA) in November 2019.

Following the recent approval, SK Biopharmaceuticals stated plans to accelerate its market strategy in Western Asia, including Israel.

Write to Yoo-Rim Kim at youfrest@hankyung.com